RIG012

CAS No. 2642218-43-5

RIG012( —— )

Catalog No. M36533 CAS No. 2642218-43-5

RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM (measured by NADH-coupled ATPase), and it inhibits the expression of IFN-β and ISG hRsad2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 169 In Stock
5MG 152 In Stock
10MG 228 In Stock
25MG 388 In Stock
50MG 522 In Stock
100MG 745 In Stock
200MG 995 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RIG012
  • Note
    Research use only, not for human use.
  • Brief Description
    RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM (measured by NADH-coupled ATPase), and it inhibits the expression of IFN-β and ISG hRsad2.
  • Description
    RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2642218-43-5
  • Formula Weight
    359.42
  • Molecular Formula
    C23H21NO3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (92.73 mM; Ultrasonic )
  • SMILES
    C(C)C1(CC)C=2C(C=3C(C(=O)C2OCC4=CC=CC=C4)=CC=CC3)=NC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. David C Rawling, et al. Small-Molecule Antagonists of the RIG-I Innate Immune Receptor. ACS Chem Biol. 2020 Feb 21;15(2):311-317.?
molnova catalog
related products
  • Przewaquinone A

    Przewaquinone A has antitumor activity.

  • OGG1-IN-O8

    OGG1-IN-O8 is an inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1;IC50 : 0.35 μM).

  • NLS-StAx-h

    Wnt inhibitor (IC50 = 1.4 μM). Stapled peptide inhibitor of oncogenic Wnt signaling. Inhibits β-catenin-transcription factor interactions. Inhibits proliferation and migration of colorectal cancer cells. Cell permeable.